This was the appeal in the action to revoke Novartis’ patent for its LESCOL® sustained release fluvastatin product. Richard Meade and Mark Chacksfield were instructed by Novartis. The appeal focused in detail on the requirements set down by the House of Lords in the recent Angiotech decision on the question of assessing inventive step.